HCC-TAG Conference | Conference

Single Priming Dose of Tremelimumab Plus Durvalumab Shows Encouraging Clinical Activity, Safety in Advanced HCC

March 28th 2021

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.

Burst of Treatment Options in HCC Complicates Sequencing Decisions

March 27th 2021

Options for systemic treatment for patients with hepatocellular carcinoma have significantly expanded since 2017, when the sole available option was sorafenib. Now, the arsenal includes checkpoint inhibitors, targeted therapies, and combinations of both classes of drugs.

Immunotherapy Begins to Make Its Way Into Early- and Intermediate-Stage HCC

March 26th 2021

Although the combination of atezolizumab and bevacizumab has become the standard frontline treatment for patients with advanced hepatocellular carcinoma, whether immunotherapy could play a role in earlier lines of treatment remains the subject of ongoing research.

Novel Combinations Flood the Frontline Treatment Landscape in Advanced HCC

March 26th 2021

Combinations of checkpoint inhibitors and VEGF TKIs, as well as dual checkpoint blockade, are affording patients with advanced hepatocellular carcinoma greater potential for disease control and deep, long-lasting responses, underscoring the need for biomarkers of response to combination regimens and single-agent TKIs, the latter of which still play a role for select populations.

Dr. Singal on Downstaging Strategies in HCC

March 26th 2021

Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.

HCC-TAG Conference to Highlight Headway Made in HCC Care Amidst COVID-19 Pandemic

March 19th 2021

Anjana Pillai, MD, discusses recent advances made in the HCC treatment paradigm, as well as what the conference will offer to healthcare providers working in the field.

Dr. Pillai on Sequential Treatment in HCC

March 16th 2021

Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.

Dr. Pillai on the Importance of Multidisciplinary Discussion in HCC

March 10th 2021

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

Biomarkers, Patient Factors Inform HCC Treatment Decisions Beyond Frontline Setting

March 3rd 2020

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

El-Khoueiry Forecasts Future of HCC Treatment Paradigm

March 3rd 2020

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.